A5073151572- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Blood groups and transfusion
- Immunotherapy and Immune Responses
- Tuberculosis Research and Epidemiology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematological disorders and diagnostics
- Virus-based gene therapy research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- Statistical Methods in Clinical Trials
- Hemostasis and retained surgical items
- Bone fractures and treatments
- Protein Degradation and Inhibitors
- Beetle Biology and Toxicology Studies
Genmab (United States)
2020-2024
Tris Pharma (United States)
2018
Novartis (United States)
2015-2018
Mount Sinai Hospital
2011-2013
Mount Sinai Medical Center
2009-2012
Columbia University
2006-2007
Memorial Hospital
2003
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS In the dose-expansion cohort of phase I/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory large and at least two prior...
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 CD20 (trimer formation) leads to activation expansion T cells killing malignant The primary objective the dose-escalation part phase I/II trial epcoritamab was determine maximum tolerated dose, recommended II dose (RP2D), or both. For bsAbs, high target saturation can negatively affect trimer formation. unique properties...
The precise role of positron emission tomography (PET/CT) for predicting relapse/progression in multiple myeloma remains uncertain. We compared the predictive values PET/CT, concurrent laboratory testing (labs), and their combination prediction 12-month progression, as determined by current International Myeloma Working Group (IMWG) criteria. PET/CT labs (serum chemistry, β2-microglobulin, immunofixation, bone marrow biopsy, serum free light chains) were reviewed, date was IMWG median time...
7523 Background: Outcomes of pts with newly diagnosed DLBCL high/poor risk according to the revised International Prognostic Index (IPI) treated immunochemotherapy (IC) remain suboptimal, a 4-year survival rate 55% (Sehn et al, Blood 2007). SC epco is well-tolerated bispecific antibody single-agent activity in relapsed/refractory (R/R) aggressive B-cell NHL setting. The mechanism action and safety profile are distinct from IC, well suited for use combinations earlier lines therapy. Addition...
7524 Background: R/R FL is associated with poor prognosis and less frequent, shorter responses each line of treatment (Tx). Although R 2 an effective regimen in acceptable safety profile, remains incurable; thus, better Tx options are needed. Subcutaneous epcoritamab a bispecific antibody that simultaneously binds to CD3 on T cells CD20 malignant B cells. In the dose-escalation part phase 1/2 EPCORE NHL-1 trial, single-agent (0.76–48 mg) resulted overall response rate 90% complete 50% FL....
Despite new therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatments with chemotherapy, single-agent rituximab/obinutuzumab, lenalidomide, combinations of these agents continue to be commonly used. This retrospective study utilized longitudinal data from 4226 real-world electronic health records characterize outcomes in patients R/R DLBCL. Eligible were diagnosed DLBCL between January 2010 and March 2022 had disease treated ≥ 1 prior systemic line therapy...
8009 Background: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results for the treatment of pts with R/R B-NHL. Epcoritamab is a novel subcutaneously administered bsAb favorable safety profile and encouraging preliminary anti-tumor activity at low doses in both aggressive indolent Here we present updated efficacy data from ongoing trial (NCT03625037). Methods: Adults CD20+ B-NHL received single SC injection flat-dose epcoritamab 28-day cycles (q1w: cycle 1–2; q2w: 3–6;...
7527 Background: Pts with R/R DLBCL who fail or are ineligible for ASCT have very poor outcomes standard palliative chemotherapy. Rituximab + GemOx had a complete response rate of 33% (Cazelles et al, Leuk Lymphoma 2021); novel approaches needed. Epco is subcutaneously administered bispecific antibody targeting CD3 on T cells and CD20 B cells. In the EPCORE NHL-1 dose-escalation trial, epco manageable safety antitumor activity in heavily pretreated B-cell NHL including DLBCL. NHL-2 phase 1/2...
TPS7592 Background: In pts with newly diagnosed DLBCL, standard treatment rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has a 5-year progression-free survival (PFS) rate of 67.0%, 58.4%, 45.8% for International Prognostic Index (IPI) 2, 3, 4–5, respectively (Ruppert et al, Blood 2020). Epcoritamab is subcutaneously administered, bispecific antibody that binds CD3 on T cells CD20 B cells, inducing potent selective T-cell–mediated killing malignant CD20+...
7518 Background: Epcoritamab is a CD20xCD3 bispecific antibody that induces T-cellmediated killing of CD20–positive malignant B-cells. We present updated data, including progression-free survival (PFS) from the dose escalation part first-in-human phase 1/2 study epcoritamab in pts with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL; NCT03625037). Methods: Adults R/R CD20+ B-NHL received flat-dose 1 mL SC (step-up dosing approach) 28-day cycles (q1w: 1–2; q2w: 3–6; q4w...
Immune thrombocytopenia (ITP) is an auto-immune disorder characterized by enhanced platelet destruction and, subsequently, the potential for increased bleeding. Thrombopoietin receptor (TPO-R) agonists have recently emerged as promising therapies ITP patients who are refractory to other treatments. While eltrombopag (EPAG) only TPO-R agonist US Food and Drug Administration approved use in pediatric patients, romiplostin (ROMI) has been used Phase III clinical studies.A cost-consequence model...
In multiple myeloma (MM), allogeneic stem cell transplantation (alloHCT) carries a lower relapse risk than autologous but greater transplant-related mortality. Nonmyeloablative conditioning for (NST) reduces toxicity. Results are encouraging when used during first remission in low-risk patients, less-so relapsed or refractory disease. This is single-center retrospective analysis of 20 previously treated MM patients who underwent NST from matched-related matched-unrelated donors 2000-2006....
Background: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins. Methods: A cost-consequence model was developed evaluate the costs relative success of EPAG, ROMI, watch rescue (W&R) in previously treated patients. The primary endpoint assessed severe bleeding, derived from all identified phase III registered clinical...
Background: Patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL) high/poor risk according to the revised International Prognostic Index (IPI) who are treated immunochemotherapy (IC) have a 4-y survival rate of 55% (Sehn et al, Blood 2007). Epcoritamab is subcutaneously administered, well-tolerated, bispecific antibody single-agent antitumor activity in relapsed/refractory (R/R) aggressive non-Hodgkin (NHL). As its mechanism action and safety profile distinct from IC,...
TPS7094 Background: Midostaurin, an orally administered multitarget kinase inhibitor, potently inhibits the FLT3 and c-Kit tyrosine kinases. Prior phase 1/2 1b clinical trials of drug have demonstrated tolerable safety profiles activity in pts with AML (Fischer, J Clin Oncol, 2010; Stone, Leukemia, 2012), it is currently development advanced mastocytosis (phase 2; Gotlib, ASH 2014) 3; ASCO 2011). In 3 randomized trial newly diagnosed, FLT3-mutated aged < 60 years, midostaurin 50 mg BID or...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Newly approved treatments for relapsed/refractory (R/R) diffuse large B-cell (DLBCL) and (LBCL) include chimeric antigen receptor T-cell (CAR T) therapy, polatuzumab vedotin plus bendamustine rituximab (pola-BR) tafasitamab lenalidomide (tafa-len). The effectiveness of pola-BR tafa-len in clinical practice has been evaluated recent real-world studies (Hamadani et al, ASH 2022; Qualls 2022). Epcoritamab, an off-the-shelf...